Publication:
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

Issued Date

2021-10-26

Resource Type

Review

ISSN

24739537
24739529

DOI

10.1182/bloodadvances.2021005493

Other identifier(s)

2-s2.0-85118298426

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Blood Advances. Vol.5, No.20 (2021), 3951-3959

Suggested Citation

Adam Cuker, Eric K. Tseng, Robby Nieuwlaat, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Jennifer Davila, Maria T. DeSancho, David Diuguid, Daniel O. Griffin, Susan R. Kahn, Frederikus A. Klok, Alfred Ian Lee, Ignacio Neumann, Ashok Pai, Marc Righini, Kristen M. Sanfilippo, Deborah Siegal, Mike Skara, Deirdra R. Terrell, Kamshad Touri, Elie A. Akl, Imad Bou Akl, Antonio Bognanni, Mary Boulos, Romina Brignardello-Petersen, Rana Charide, Matthew Chan, Karin Dearness, Andrea J. Darzi, Philipp Kolb, Luis E. Colunga-Lozano, Razan Mansour, Gian Paolo Morgano, Rami Z. Morsi, Giovanna Muti-Schunemann, Atefeh Noori, Binu A. Philip, Thomas Piggott, Yuan Qiu, Yetiani Roldan, Finn Schunemann, Adrienne Stevens, Karla Solo, Wojtek Wiercioch, Reem A. Mustafa, Holger J. Schunemann American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances. Vol.5, No.20 (2021), 3951-3959. doi:10.1182/bloodadvances.2021005493 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77762

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

Author(s)

Adam Cuker
 Eric K. Tseng
 Robby Nieuwlaat
 Pantep Angchaisuksiri
 Clifton Blair
 Kathryn Dane
 Jennifer Davila
 Maria T. DeSancho
 David Diuguid
 Daniel O. Griffin
 Susan R. Kahn
 Frederikus A. Klok
 Alfred Ian Lee
 Ignacio Neumann
 Ashok Pai
 Marc Righini
 Kristen M. Sanfilippo
 Deborah Siegal
 Mike Skara
 Deirdra R. Terrell
 Kamshad Touri
 Elie A. Akl
 Imad Bou Akl
 Antonio Bognanni
 Mary Boulos
 Romina Brignardello-Petersen
 Rana Charide
 Matthew Chan
 Karin Dearness
 Andrea J. Darzi
 Philipp Kolb
 Luis E. Colunga-Lozano
 Razan Mansour
 Gian Paolo Morgano
 Rami Z. Morsi
 Giovanna Muti-Schunemann
 Atefeh Noori
 Binu A. Philip
 Thomas Piggott
 Yuan Qiu
 Yetiani Roldan
 Finn Schunemann
 Adrienne Stevens
 Karla Solo
 Wojtek Wiercioch
 Reem A. Mustafa
 Holger J. Schunemann

Other Contributor(s)

Ramathibodi Hospital
 Michael G. DeGroote School of Medicine
 School of Medicine
 Albert Ludwigs Universität Freiburg, Medizinische Fakultät
 American University of Beirut
 King Hussein Cancer Center
 McMaster University
 University of Oklahoma Health Sciences Center
 Pontificia Universidad Católica de Chile
 The University of Chicago
 Universitätsklinikum Freiburg
 Penn Medicine
 Washington University School of Medicine in St. Louis
 New York Presbyterian Hospital
 Yale School of Medicine
 Kaiser Permanente
 Saint Michael's Hospital University of Toronto
 Leids Universitair Medisch Centrum
 Vagelos College of Physicians and Surgeons
 St. Joseph's Healthcare Hamilton
 Hôpitaux Universitaires de Genève
 Universidad de Guadalajara
 University of Kansas Medical Center
 Albert Einstein College of Medicine of Yeshiva University
 Ottawa Hospital Research Institute
 The Johns Hopkins Hospital
 Research and Development at United Health Group Minnetonka
 NJ
 Prohealth NY

Abstract

Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Methods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021. Results: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Conclusions: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/77762

Collections

Scopus 2021